Heterocyclic compound, preparation method thereof and application of heterocyclic compound in preparation of GLP-1 receptor agonist prodrug with oral PK characteristic and long-acting PK characteristic

CN122138966APending Publication Date: 2026-06-02HINOVA PHARM INC
0 Cites 0 Cited by

Patent Information

Application Number
CN202580002198.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-10-01
Filing Date
2025-09-30
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Existing GLP-1R agonists, as small molecule drugs, have low bioavailability, poor pharmacokinetic properties, and may cause gastrointestinal side effects, which limits their clinical application.

Method used

A heterocyclic compound and its preparation method are provided for preparing a GLP-1 receptor agonist prodrug with oral PK characteristics and long-acting PK characteristics. The compound structure is optimized to improve the bioavailability of the drug and reduce side effects.

Benefits of technology

It improves the bioavailability of GLP-1 receptor agonists, reduces gastrointestinal side effects, enhances the pharmacokinetic properties of the drug, and expands its potential for clinical application.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a heterocyclic compound, a preparation method thereof and application of the heterocyclic compound in preparation of a GLP-1 receptor agonist prodrug with oral PK characteristics and long-acting PK characteristics, and belongs to the field of medicinal chemistry. The compound provided by the invention can be used as a GLP-1 receptor agonist prodrug, and the GLP-1 receptor agonist prodrug compound can be hydrolyzed in vivo to release a parent drug with a GLP-1 receptor agonist effect. The compound provided by the invention can be used as a GLP-1 receptor agonist prodrug compound, and is used for preparing drugs for preventing and / or treating diseases related to GLP-1 receptors. The compound provided by the invention has good oral administration and long-acting pharmacokinetics, has better medication compliance, and has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art